Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits
In 2025, the company reported a -1.73% YoY (Jan-Dec25) decline in revenue, reflecting portfolio dynamics: Entyvio ($6.14B) continues to anchor growth in inflammatory bowel disease, Takhzyro ($1.44B) shows steady momentum in rare diseases, while Gattex/Revestive ($913.56M) remains a solid contributor in gastrointestinal disorders partially offset by generic pressure and loss of exclusivity in some legacy products
Increasing Investment in R&D Increasing investment in R&D is another major factor driving the growth of the GLP-1 targeted peptide weight loss drugs market, as it accelerates the development of more effective, longer-acting, and patient-friendly therapies
As demand for these treatments skyrockets, Novo continues to push the boundaries, investing in new weight loss medications and reshaping the future of metabolic health
Senna: Is a natural herbal laxative that stimulates the muscles in the intestines, promoting bowel movements
Should I take vitamins or supplements for my skin
